EMD-18258

Helical reconstruction
2.1 Å
EMD-18258 Deposition: 18/08/2023
Map released: 20/09/2023
Last modified: 17/01/2024
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links

EMD-18258

Tau - AD-PHF

EMD-18258

Helical reconstruction
2.1 Å
EMD-18258 Deposition: 18/08/2023
Map released: 20/09/2023
Last modified: 17/01/2024
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links
Sample Organism: Homo sapiens
Sample: Amyloid
Fitted models: 8q8r (Avg. Q-score: 0.684)

Deposition Authors: Lovestam S, Li D , Scheres SHW , Goedert M
Disease-specific tau filaments assemble via polymorphic intermediates.
PUBMED: 38030728
DOI: doi:10.1038/s41586-023-06788-w
ISSN: 1476-4687
ASTM: NATUAS
Abstract:
Intermediate species in the assembly of amyloid filaments are believed to play a central role in neurodegenerative diseases and may constitute important targets for therapeutic intervention1,2. However, structural information about intermediate species has been scarce and the molecular mechanisms by which amyloids assemble remain largely unknown. Here we use time-resolved cryogenic electron microscopy to study the in vitro assembly of recombinant truncated tau (amino acid residues 297-391) into paired helical filaments of Alzheimer's disease or into filaments of chronic traumatic encephalopathy3. We report the formation of a shared first intermediate amyloid filament, with an ordered core comprising residues 302-316. Nuclear magnetic resonance indicates that the same residues adopt rigid, β-strand-like conformations in monomeric tau. At later time points, the first intermediate amyloid disappears and we observe many different intermediate amyloid filaments, with structures that depend on the reaction conditions. At the end of both assembly reactions, most intermediate amyloids disappear and filaments with the same ordered cores as those from human brains remain. Our results provide structural insights into the processes of primary and secondary nucleation of amyloid assembly, with implications for the design of new therapies.